News

The neuropharmacologist at the University of Lille, in France, provided commentary on promising results from the phase 1/2 DIVE-I trial assessing the safety and efficacy of a device-assisted therapy in Parkinson disease. [WATCH TIME: 6 minutes]

While participants responded positively to nutritional guidance and the Mediterranean diet, they expressed negative views on the ketogenic diet due to its restrictive nature, social impracticality, and gastrointestinal side effects of MCT oil.

Patients reported increased good ON time and improved confidence in daily activities while experiencing a lower treatment burden compared to their previous medication regimens.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on cryptogenic stroke.

Lu AF84222 was considered well tolerated, with greater treatment effects observed in a subgroup of patients with less impaired multiple system atrophy.

Path to Prevention is a platform, phase 2 trial that will investigate the safety and efficacy of investigational interventions in patients neuronal α-synuclein disease stage 2B.

Findings from a new study presented at MDS 2024 suggest that variations in cholinergic denervation patterns may hold promise for differentiating Parkinson disease and progressive supranuclear palsy with parkinsonism.

Despite showing no differences vs placebo on the primary end point of gait parameters, TAK-071-treated patients demonstrated significant improvements in global cognition score.

Neurology News Network. for the week ending September 28, 2024. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 27, 2024.

Tim Miller, MD, director of functional neurosurgery at the Marcus Neuroscience Institute, Baptist Health, provided commentary on the use of HIFU as a non-invasive treatment for patients with essential tremor and specific types of Parkinson disease.

The consultant neurologist at Queen's Square MS Center in London gave his clinical viewpoint on the newest revision of the McDonald criteria for diagnosing patients with multiple sclerosis. [WATCH TIME: 3 minutes]

Innovative neurosurgical advances in imaging/mapping, robotic assistance, and extended reality enable surgeons to more precisely and effectively treat neurological conditions such as brain tumor, epilepsy, Parkinson Disease, and stroke, giving patients new hope and a chance for more successful outcomes.

Results from the phase 3 TEMPO-2 trial, an additional study assessing tavapadon as a flexible-dose monotherapy, are expected by the end of this year.

A pair of neurologists from the University of California, Irvine, detailed some of the training and career focuses of large federal agencies in effort to address the shortage of neurologists. [WATCH TIME: 4 minutes]

RNS60 may lengthen survival by slowing FVC progression, particularly in participants with low NfL and MCP-1 levels at baseline, suggesting a potential target subgroup for future studies.

The chief research officer of the Muscular Dystrophy Association talked about what is to be expected at the 2025 MDA Conference, held March 16-19, in Dallas, Texas. [WATCH TIME: 5 minutes]

The company expects to complete the trial in Q1 2025 and anticipates it will use the feedback from regulators to guide an accelerated approval.

The approval follows phase 3 data that showed significant improvements in neurological symptoms and functional benefit over 12 weeks in patients with Niemann-Pick disease type C.

Zevra Therapeutics plans to immediately start its launch activities for arimoclomol, marketed as Miplyffa, which is anticipated to be commercially available in 8 to 12 weeks in the United States.

The postdoctoral researcher at Amsterdam University Medical Center talked about the DAAE score 2.0 which offers an improved, validated clinical tool to predict the risk of transitioning to secondary progressive multiple sclerosis. [WATCH TIME: 5 minutes]

The consultant neurologist at Queen's Square MS Center in London discussed the shift in the updates to the McDonald criteria for multiple sclerosis presented at ECTRIMS 2024.

Recruitment for the OCTOPUS trial, which explores alpha-lipoic acid and metformin in progressive multiple sclerosis (MS), is progressing well with nearly half of participants in stage 1 already randomized.

Representatives from the SCN8A Alliance discussed ways to improve the quality of life for children with SCN8A-related epilepsy, highlighting the critical role of early genetic diagnosis and targeted interventions. [WATCH TIME: 4 minutes]

The phase 1b/2a dose escalation trial of KINE-101, conducted in Korea, includes patients with chronic inflammatory demyelinating polyneuropathy who have received at least 1 frontline treatment regimen.

Neal K. Shah, CEO of CareYaya Health Technologies, discussed a miniaturized brain-machine interface developed that could restore communication for patients with neurological disorders by translating brain activity into text.

In the study, patients with spinocerebellar ataxia treated with troriluzole demonstrated statistically significant improvements at years 1 and 2 on the treatment.

Stewart Tepper, MD, Vice President at the New England Institute for Neurology and Headache in Stamford, Connecticut, provided commentary on a wide-scale analysis of nearly 5000 patients testing the effects of rimegepant.